The RaDAR project aims to address the European urgent need for rapid detection of multi-drug resistant microorganisms (MDROs) and antimicrobial resistance (AMR) management and control systems, through the implementation of a value-based cross-border collaborative procurement of innovative solutions.
RaDAR was launched in 2022 under the auspices of European Innovation Council and SMEs Executive Agency (EISMEA) and its COSME programme.
The project involves a cross-border consortium of nine partners from three different European countries (France, Spain and Italy). Four organisations make up the Buyers Group (RESAH, ICO, OSAK, UNINA), in addition to five supporting entities (AquAS, Biodonostia, INSERM, INSME, JERA).
AMR is a major health threat worldwide, with annual deaths resulting from antimicrobial-resistant infections estimated to reach up to 10 million a year in 2050, with the COVID-19 pandemic only exacerbating the challenge.
Innovation is needed to rapidly detect and control AMR in a number of settings, not least healthcare facilities and hospitals. The RaDAR project brings together healthcare public buyers to undertake a collaborative public procurement of innovation of rapid AMR detection and control systems.
